The guidelines for the treatment of patients with lung cancer are based on a number of factors including disease type and patient considerations. The cancer treatment guidelines below offer a concise description of National Comprehensive Cancer Network (NCCN) guidelines for mesothelioma, non-small cell lung cancer, and small cell lung cancer.
The lung cancer treatment regimens include chemotherapy regimens for neoadjuvant and adjuvant therapy, sequential chemotherapy/radiotherapy, concurrent chemotherapy/radiotherapy followed by chemotherapy, and systemic therapy for advanced disease. The regimens also outline principles of maintenance therapy and subsequent therapy.
The mesothelioma treatment regimens include guidelines for first-line and second-line chemotherapies such as pemetrexed + carboplatin, gemcitabine + cisplatin, vinorelbine, pemetrexed + cisplatin + bevacizumab, and gemcitabine.
The lung cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. These regimens are only provided to supplement the latest treatment strategies.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Alcohol Consumption and Cancer
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Depressed Patients With Head and Neck Cancer May Have Higher Mortality Rates
- MSK1 Levels Associated With Relapse, Metastasis in ER-positive Breast Cancer
- In the Clinic: Managing Malignant Pleural Effusions
- Does Depression Increase the Risk for Mortality Among Patients With Cancer?
- Nivolumab With Ipilimumab Promising for Pretreated Metastatic Sarcoma